JAKARTA. PT Prodia Widyahusada Tbk (PRDA) is optimistic that it could maintain a satisfactory performance by the end of 2021. Although several COVID-19-related tests are decreasing in demand, PRDA could still earn revenue from genomic and routine tests.
“By far, the performance realisation in Q3 2021 is still on the right track to the target. We are confident in keeping the good performance by the end of 2021,” Dewi Muliaty, President Director of Prodia, told Bisnis, quoted Thursday (7/10). She reassured the media that the official report for Q3 2021 performance would be released by the end of October or early November 2021.
According to Muliaty, the revenue composition during this pandemic is still dominated by genomic and routine tests with 80%. In contrast, COVID-19-related tests like PCR, Rapid Tests, and Antigen Tests contribute only 18% to the company’s total revenue.
From the start, Prodia’s strategy and mission are indeed to develop special and latest examination tests that follow laboratory science and technology. Thus, they include genomic tests and personalised medical check-ups. (AM/ZH)